# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
278, Journal, 0, 11, "Clin Ther .", "", "<http://ctro/data#Publication_43296> <http://ctro/data#hasJournal> \"Clin Ther .\"."
0, PublicationYear, 12, 16, "2007", "", "<http://ctro/data#Publication_43296> <http://ctro/data#hasPublicationYear> \"2007\"."
132, Title, 44, 284, "Results of the glucose - lowering effect of WelChol study ( GLOWS ) : a randomized , double - blind , placebo - controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes .", "", "<http://ctro/data#Publication_43296> <http://ctro/data#hasTitle> \"Results of the glucose - lowering effect of WelChol study ( GLOWS ) : a randomized , double - blind , placebo - controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes .\"."
1, Randomized, 116, 126, "randomized", "", "<http://ctro/data#ClinicalTrial_43307> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
2, DoubleBlind, 129, 143, "double - blind", "", "<http://ctro/data#ClinicalTrial_43307> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
129, Placebo, 146, 153, "placebo", "", 
79868, Colesevelam, 204, 229, "colesevelam hydrochloride", "", 
4, Type2Diabetes, 267, 282, "type 2 diabetes", "", 
5, Author, 285, 293, "Zieve FJ", "", "<http://ctro/data#Publication_43296> <http://ctro/data#hasAuthor> \"Zieve FJ\"."
6, Author, 302, 310, "Kalin MF", "", "<http://ctro/data#Publication_43296> <http://ctro/data#hasAuthor> \"Kalin MF\"."
7, Author, 313, 324, "Schwartz SL", "", "<http://ctro/data#Publication_43296> <http://ctro/data#hasAuthor> \"Schwartz SL\"."
8, Author, 327, 335, "Jones MR", "", "<http://ctro/data#Publication_43296> <http://ctro/data#hasAuthor> \"Jones MR\"."
9, Author, 338, 347, "Bailey WL", "", "<http://ctro/data#Publication_43296> <http://ctro/data#hasAuthor> \"Bailey WL\"."
10, USA, 451, 454, "USA", "", "<http://ctro/data#Population_43326> <http://ctro/data#hasCountry> <http://ctro/data#USA>."
281, ObjectiveDescription, 494, 736, "This study evaluated the glycosylated hemoglobin ( HbA ( 1c ) - lowering effect of colesevelam hydrochloride , a bile acid sequestrant , in subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy .", "", "<http://ctro/data#ClinicalTrial_43307> <http://ctro/data#hasObjectiveDescription> \"This study evaluated the glycosylated hemoglobin ( HbA ( 1c ) - lowering effect of colesevelam hydrochloride , a bile acid sequestrant , in subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy .\"."
11, HbA1c, 519, 542, "glycosylated hemoglobin", "", 
12, HbA1c, 545, 555, "HbA ( 1c )", "", 
79869, Colesevelam, 577, 602, "colesevelam hydrochloride", "", 
15, Precondition, 634, 734, "subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy", "", "<http://ctro/data#Population_43326> <http://ctro/data#hasPrecondition> \"subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy\"."
14, Type2Diabetes, 648, 663, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_43307> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
151, Duration, 755, 763, "4 - week", "", 
16, Placebo, 764, 771, "placebo", "", 
21, Precondition, 790, 866, "subjects with type 2 diabetes and an HbA ( 1c ) value of 7 . 0 % to 10 . 0 %", "", "<http://ctro/data#Population_43326> <http://ctro/data#hasPrecondition> \"subjects with type 2 diabetes and an HbA ( 1c ) value of 7 . 0 % to 10 . 0 %\"."
17, Type2Diabetes, 804, 819, "type 2 diabetes", "", 
18, HbA1c, 827, 837, "HbA ( 1c )", "", 
19, Percentage, 853, 854, "%", "", 
20, Percentage, 865, 866, "%", "", 
22, Randomized, 872, 882, "randomized", "", 
79870, Colesevelam, 894, 905, "colesevelam", "", "<http://ctro/data#Medication_43489> <http://ctro/data#hasDrug> <http://ctro/data#Colesevelam>."
24, DoseValue, 906, 912, "3 . 75", "", "<http://ctro/data#Medication_43489> <http://ctro/data#hasDoseValue> \"3 . 75\"."
25, Gram, 913, 914, "g", "", "<http://ctro/data#Medication_43489> <http://ctro/data#hasDoseUnit> <http://ctro/data#Gram>."
49128, Interval, 917, 918, "d", "", "<http://ctro/data#Intervention_43477> <http://ctro/data#hasInterval> \"d\"."
26, Placebo, 931, 938, "placebo", "", "<http://ctro/data#Medication_43496> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
27, Duration, 943, 951, "12 weeks", "", "<http://ctro/data#ClinicalTrial_43307> <http://ctro/data#hasCTduration> \"12 weeks\"."
28, OralAntidiabeticAgent, 974, 1008, "oral anti hyperglycemic medication", "", 
29, Sulfonylureas, 1011, 1023, "sulfonylurea", "", 
30, Metformin, 1033, 1042, "metformin", "", 
31, FastingPlasmaGlucose, 1082, 1095, "Fasting blood", "", 
299, TimePoint, 1121, 1130, "weeks - 5", "", 
300, TimePoint, 1121, 1136, "weeks - 5 , - 1", "", 
301, TimePoint, 1121, 1140, "weeks - 5 , - 1 , 0", "", 
302, TimePoint, 1121, 1144, "weeks - 5 , - 1 , 0 , 1", "", 
303, TimePoint, 1121, 1148, "weeks - 5 , - 1 , 0 , 1 , 4", "", 
304, TimePoint, 1121, 1152, "weeks - 5 , - 1 , 0 , 1 , 4 , 8", "", 
305, TimePoint, 1121, 1161, "weeks - 5 , - 1 , 0 , 1 , 4 , 8 , and 12", "", 
32, HbA1c, 1213, 1223, "HbA ( 1c )", "", 
283, TimePoint, 1229, 1237, "baseline", "", 
162, TimePoint, 1241, 1248, "week 12", "", 
33, Fructosamine, 1292, 1304, "fructosamine", "", 
34, FastingPlasmaGlucose, 1314, 1336, "fasting plasma glucose", "", 
285, PostprandialBloodGlucose, 1346, 1366, "postprandial glucose", "", "<http://ctro/data#ClinicalTrial_43307> <http://ctro/data#hasObjectiveDescription> \"This study evaluated the glycosylated hemoglobin ( HbA ( 1c ) - lowering effect of colesevelam hydrochloride , a bile acid sequestrant , in subjects with type 2 diabetes that was inadequately controlled by existing antihyperglycemic therapy .\"."
35, MealGlucoseResponse, 1379, 1400, "meal glucose response", "", 
36, EndPointDescription, 1490, 1506, "lipid parameters", "", 
168, TimePoint, 1512, 1520, "baseline", "", 
169, TimePoint, 1524, 1531, "week 12", "", 
37, NumberPatientsCT, 1548, 1550, "65", "", "<http://ctro/data#ClinicalTrial_43307> <http://ctro/data#hasNumberPatientsCT> \"65\"."
38, Randomized, 1551, 1561, "randomized", "", 
39, NumberPatientsArm, 1573, 1575, "31", "", "<http://ctro/data#Arm_43459> <http://ctro/data#hasNumberPatientsArm> \"31\"."
79871, Colesevelam, 1576, 1587, "colesevelam", "", 
40, NumberPatientsArm, 1590, 1592, "34", "", "<http://ctro/data#Arm_43468> <http://ctro/data#hasNumberPatientsArm> \"34\"."
42, Placebo, 1593, 1600, "placebo", "", 
306, Mean, 1609, 1613, "mean", "", 
43, AvgAge, 1621, 1627, "56 . 2", "", "<http://ctro/data#Population_43326> <http://ctro/data#hasAvgAge> \"56 . 2\"."
44, BMI, 1645, 1660, "body mass index", "", 
178, Kg_per_squareMeter, 1671, 1683, "kg / m ( 2 )", "", 
46, Male, 1686, 1704, "55 . 4 % were male", "", "<http://ctro/data#Population_43326> <http://ctro/data#hasGender> <http://ctro/data#Male>."
47, Ethnicity, 1709, 1728, "53 . 8 % were white", "", "<http://ctro/data#Ethnicity_43328> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Ethnicity>. <http://ctro/data#Population_43326> <http://ctro/data#hasEthnicity> <http://ctro/data#Ethnicity_43328>."
189, LeastSquaresMean, 1749, 1774, "least squares ( LS ) mean", "", "<http://ctro/data#Endpoint_43335> <http://ctro/data#hasAggregationMethod> <http://ctro/data#LeastSquaresMean>."
48, HbA1c, 1792, 1802, "HbA ( 1c )", "", "<http://ctro/data#Endpoint_43335> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
79872, Colesevelam, 1815, 1826, "colesevelam", "", 
50, Placebo, 1841, 1848, "placebo", "", 
118, DiffGroupAbsValue, 1859, 1866, "- 0 . 5", "", "<http://ctro/data#DiffBetweenGroups_13651> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 5\"."
119, Percentage, 1867, 1868, "%", "", "<http://ctro/data#Endpoint_43335> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
120, SdErrorDiff, 1871, 1877, "0 . 18", "", "<http://ctro/data#DiffBetweenGroups_13651> <http://ctro/data#hasStandardErrorDiff> \"0 . 18\"."
51, PvalueDiff, 1882, 1893, "P = 0 . 007", "", "<http://ctro/data#DiffBetweenGroups_13651> <http://ctro/data#hasPvalueDiff> \"P = 0 . 007\"."
52, SubGroupDescription, 1901, 1946, "subjects with a baseline HbAIc > or = 8 . 0 %", "", "<http://ctro/data#Outcome_43557> <http://ctro/data#hasSubGroupDescription> \"subjects with a baseline HbAIc > or = 8 . 0 %\". <http://ctro/data#Outcome_43584> <http://ctro/data#hasSubGroupDescription> \"subjects with a baseline HbAIc > or = 8 . 0 %\"."
53, HbA1c, 1926, 1931, "HbAIc", "", "<http://ctro/data#Outcome_43557> <http://ctro/data#hasSubGroupDescription> \"subjects with a baseline HbAIc > or = 8 . 0 %\". <http://ctro/data#Outcome_43584> <http://ctro/data#hasSubGroupDescription> \"subjects with a baseline HbAIc > or = 8 . 0 %\"."
54, Percentage, 1945, 1946, "%", "", 
193, LeastSquaresMean, 1967, 1974, "LS mean", "", 
55, HbA1c, 1985, 1995, "HbA ( 1c )", "", 
121, DiffGroupAbsValue, 2000, 2007, "- 1 . 0", "", "<http://ctro/data#DiffBetweenGroups_43611> <http://ctro/data#hasDiffGroupAbsValue> \"- 1 . 0\"."
122, Percentage, 2008, 2009, "%", "", "<http://ctro/data#DiffBetweenGroups_43611> <http://ctro/data#hasDiffGroupAbsValue> \"- 1 . 0\"."
196, SdErrorDiff, 2012, 2018, "0 . 27", "", "<http://ctro/data#DiffBetweenGroups_43611> <http://ctro/data#hasStandardErrorDiff> \"0 . 27\"."
56, PvalueDiff, 2023, 2034, "P = 0 . 002", "", "<http://ctro/data#DiffBetweenGroups_43611> <http://ctro/data#hasPvalueDiff> \"P = 0 . 002\"."
57, Placebo, 2051, 2058, "placebo", "", 
79877, Colesevelam, 2061, 2072, "colesevelam", "", 
59, Fructosamine, 2127, 2139, "fructosamine", "", "<http://ctro/data#Endpoint_43340> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Fructosamine>."
60, Reduction, 2144, 2150, "29 . 0", "", "<http://ctro/data#Outcome_43620> <http://ctro/data#hasChangeValue> \"29 . 0\"."
124, ResultMeasuredValue, 2153, 2159, "10 . 9", "", "<http://ctro/data#Outcome_43620> <http://ctro/data#hasResultMeasuredValue> \"10 . 9\"."
61, Picomole_per_liter, 2162, 2170, "pmol / L", "", "<http://ctro/data#Endpoint_43340> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Picomole_per_liter>."
62, PValueChangeValue, 2173, 2184, "P = 0 . 011", "", "<http://ctro/data#Outcome_43620> <http://ctro/data#hasPValueChangeValue> \"P = 0 . 011\"."
290, PostprandialBloodGlucose, 2191, 2211, "postprandial glucose", "", "<http://ctro/data#Endpoint_43345> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#PostprandialBloodGlucose>."
63, Reduction, 2216, 2222, "31 . 5", "", "<http://ctro/data#Outcome_43647> <http://ctro/data#hasChangeValue> \"31 . 5\"."
64, ResultMeasuredValue, 2225, 2231, "13 . 6", "", "<http://ctro/data#Outcome_43647> <http://ctro/data#hasResultMeasuredValue> \"13 . 6\"."
65, Mg_per_deciliter, 2234, 2241, "mg / dL", "", "<http://ctro/data#Endpoint_43345> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Mg_per_deciliter>."
66, PValueChangeValue, 2244, 2255, "P = 0 . 026", "", "<http://ctro/data#Outcome_43647> <http://ctro/data#hasPValueChangeValue> \"P = 0 . 026\"."
215, Mean, 2264, 2268, "mean", "", "<http://ctro/data#Mean_43352> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_43350> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_43352>."
67, EndPointDescription, 2287, 2324, "low - density lipoprotein cholesterol", "", "<http://ctro/data#EndPointDescription_43351> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_43350> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_43351>."
68, RelativeReduction, 2331, 2336, "9 . 6", "", "<http://ctro/data#Outcome_43674> <http://ctro/data#hasRelativeChangeValue> \"9 . 6\"."
79873, Colesevelam, 2346, 2357, "colesevelam", "", 
291, RelativeIncrement, 2380, 2385, "2 . 1", "", "<http://ctro/data#Outcome_43710> <http://ctro/data#hasRelativeChangeValue> \"2 . 1\"."
70, Placebo, 2395, 2402, "placebo", "", 
49225, DiffGroupRelValue, 2434, 2442, "- 11 . 7", "", "<http://ctro/data#DiffBetweenGroups_43738> <http://ctro/data#hasDiffGroupRelValue> \"- 11 . 7\"."
72, DiffGroupAbsValue, 2447, 2452, "4 . 2", "", "<http://ctro/data#DiffBetweenGroups_43738> <http://ctro/data#hasDiffGroupAbsValue> \"4 . 2\"."
73, PvalueDiff, 2457, 2468, "P = 0 . 007", "", "<http://ctro/data#DiffBetweenGroups_43738> <http://ctro/data#hasPvalueDiff> \"P = 0 . 007\"."
224, Mean, 2488, 2492, "mean", "", "<http://ctro/data#Mean_43357> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_43355> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_43357>."
74, EndPointDescription, 2512, 2529, "total cholesterol", "", "<http://ctro/data#EndPointDescription_43356> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_43355> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_43356>."
75, RelativeReduction, 2537, 2542, "4 . 0", "", "<http://ctro/data#Outcome_43748> <http://ctro/data#hasRelativeChangeValue> \"4 . 0\"."
49226, RelativeIncrement, 2549, 2554, "3 . 4", "", "<http://ctro/data#Outcome_43775> <http://ctro/data#hasRelativeChangeValue> \"3 . 4\"."
49227, DiffGroupRelValue, 2582, 2589, "- 7 . 3", "", "<http://ctro/data#DiffBetweenGroups_43802> <http://ctro/data#hasDiffGroupRelValue> \"- 7 . 3\"."
78, DiffGroupAbsValue, 2594, 2599, "3 . 0", "", "<http://ctro/data#DiffBetweenGroups_43802> <http://ctro/data#hasDiffGroupAbsValue> \"3 . 0\"."
79, PvalueDiff, 2604, 2615, "P = 0 . 019", "", "<http://ctro/data#DiffBetweenGroups_43802> <http://ctro/data#hasPvalueDiff> \"P = 0 . 019\"."
79874, Colesevelam, 2620, 2631, "Colesevelam", "", 
238, ObservedResult, 2657, 2678, "significant decreases", "", "<http://ctro/data#Outcome_43811> <http://ctro/data#hasObservedResult> \"significant decreases\"."
81, EndPointDescription, 2704, 2720, "apolipoprotein B", "", "<http://ctro/data#EndPointDescription_43361> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_43360> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_43361>."
82, PValueChangeValue, 2723, 2734, "P = 0 . 003", "", "<http://ctro/data#Outcome_43811> <http://ctro/data#hasPValueChangeValue> \"P = 0 . 003\"."
83, EndPointDescription, 2741, 2789, "low - density lipoprotein particle concentration", "", "<http://ctro/data#EndPointDescription_43366> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_43365> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_43366>."
84, PValueChangeValue, 2792, 2803, "P = 0 . 037", "", "<http://ctro/data#Outcome_43838> <http://ctro/data#hasPValueChangeValue> \"P = 0 . 037\"."
116, EndPointDescription, 2812, 2860, "incidence of treatment - emergent adverse events", "", "<http://ctro/data#EndPointDescription_43371> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_43370> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_43371>."
117, EndPointDescription, 2863, 2868, "TEAEs", "", 
87, ObservedResult, 2871, 2897, "was similar in both groups", "", "<http://ctro/data#Outcome_43865> <http://ctro/data#hasObservedResult> \"was similar in both groups\"."
242, EndPointDescription, 2929, 2943, "adverse events", "", "<http://ctro/data#EndPointDescription_43376> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_43375> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_43376>."
49224, ObservedResult, 2944, 2987, "were more frequent in the colesevelam group", "", "<http://ctro/data#Outcome_43892> <http://ctro/data#hasObservedResult> \"were more frequent in the colesevelam group\"."
79875, Colesevelam, 2970, 2981, "colesevelam", "", 
86, Placebo, 3000, 3007, "placebo", "", 
89, PercentageAffected, 3016, 3022, "29 . 0", "", "<http://ctro/data#Outcome_43892> <http://ctro/data#hasPercentageAffected> \"29 . 0\"."
90, PercentageAffected, 3028, 3033, "8 . 8", "", "<http://ctro/data#Outcome_43919> <http://ctro/data#hasPercentageAffected> \"8 . 8\"."
79876, Colesevelam, 3086, 3097, "colesevelam", "", 
91, GastrointestinalProblem, 3109, 3135, "gastrointestinal disorders", "", "<http://ctro/data#Endpoint_43380> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#GastrointestinalProblem>."
93, PercentageAffected, 3138, 3144, "22 . 6", "", "<http://ctro/data#Outcome_43947> <http://ctro/data#hasPercentageAffected> \"22 . 6\"."
257, EndPointDescription, 3151, 3173, "primarily constipation", "", "<http://ctro/data#EndPointDescription_43386> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_43385> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_43386>."
94, PercentageAffected, 3176, 3182, "19 . 4", "", "<http://ctro/data#Outcome_43974> <http://ctro/data#hasPercentageAffected> \"19 . 4\"."
96, PercentageAffected, 3206, 3211, "8 . 8", "", "<http://ctro/data#Outcome_44001> <http://ctro/data#hasPercentageAffected> \"8 . 8\"."
97, GastrointestinalProblem, 3227, 3253, "gastrointestinal disorders", "", 
99, PercentageAffected, 3256, 3257, "0", "", 
258, EndPointDescription, 3260, 3272, "constipation", "", "<http://ctro/data#EndPointDescription_43391> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_43390> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_43391>."
98, Placebo, 3282, 3289, "placebo", "", 
292, ObservedResult, 3298, 3407, "There were no significant changes in body weight or the occurrence of hypoglycemia between treatment groups .", "", "<http://ctro/data#Outcome_44055> <http://ctro/data#hasObservedResult> \"There were no significant changes in body weight or the occurrence of hypoglycemia between treatment groups .\". <http://ctro/data#Outcome_44082> <http://ctro/data#hasObservedResult> \"There were no significant changes in body weight or the occurrence of hypoglycemia between treatment groups .\"."
101, BodyWeight, 3335, 3346, "body weight", "", "<http://ctro/data#Endpoint_43395> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
102, Hypoglycemia, 3368, 3380, "hypoglycemia", "", "<http://ctro/data#Endpoint_43427> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
270, ConclusionComment, 3422, 3630, "In these subjects with type 2 diabetes , 12 weeks of colesevelam treatment were associated with significant reductions in HbA ( 1c ) and in fructosamine and postprandial glucose levels compared with placebo .", "", "<http://ctro/data#ClinicalTrial_43307> <http://ctro/data#hasConclusionComment> \"In these subjects with type 2 diabetes , 12 weeks of colesevelam treatment were associated with significant reductions in HbA ( 1c ) and in fructosamine and postprandial glucose levels compared with placebo .\"."
103, Type2Diabetes, 3445, 3460, "type 2 diabetes", "", 
104, Duration, 3463, 3471, "12 weeks", "", 
79878, Colesevelam, 3475, 3486, "colesevelam", "", 
106, HbA1c, 3544, 3554, "HbA ( 1c )", "", 
107, Fructosamine, 3562, 3574, "fructosamine", "", 
298, PostprandialBloodGlucose, 3579, 3599, "postprandial glucose", "", 
108, Placebo, 3621, 3628, "placebo", "", 
272, ConclusionComment, 3631, 3771, "The 2 groups had a similar adverse - event profile , with the exception of an increased incidence of constipation in the colesevelam group .", "", "<http://ctro/data#ClinicalTrial_43307> <http://ctro/data#hasConclusionComment> \"The 2 groups had a similar adverse - event profile , with the exception of an increased incidence of constipation in the colesevelam group .\"."
49223, EndPointDescription, 3658, 3681, "adverse - event profile", "", 
109, Constipation, 3732, 3744, "constipation", "", 
79880, Colesevelam, 3752, 3763, "colesevelam", "", 
276, ConclusionComment, 3772, 3942, "These results suggest that colesevelam may improve both lipid control and glycemic control in patients with type 2 diabetes receiving oral antihyperglycemic medications .", "", "<http://ctro/data#ClinicalTrial_43307> <http://ctro/data#hasConclusionComment> \"These results suggest that colesevelam may improve both lipid control and glycemic control in patients with type 2 diabetes receiving oral antihyperglycemic medications .\"."
79879, Colesevelam, 3799, 3810, "colesevelam", "", 
114, Type2Diabetes, 3880, 3895, "type 2 diabetes", "", 
297, OralAntidiabeticAgent, 3906, 3940, "oral antihyperglycemic medications", "", 
115, PMID, 4000, 4008, "17379048", "", "<http://ctro/data#Publication_43296> <http://ctro/data#hasPMID> \"17379048\"."
